VTGN VistaGen Therapeutics Inc.

0.8
+0.06  (+8%)
Previous Close 0.74
Open 0.74
Price To Book 20
Market Cap 32896372
Shares 41,120,465
Volume 631,961
Short Ratio
Av. Daily Volume 406,603

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 3Q 2019.
AV-101
Adjunctive Treatment Major Depressive Disorder
Phase 2 data due 2019.
AV-101
Monotherapy Treatment Major Depressive Disorder
Phase 2 trial planned.
AV-101
Neuropathic pain
Phase 3 pivotal program to be initiated in 2020. Target completion YE 2021.
PH94B nasal spray
Social Anxiety Disorder (SAD)

Latest News

  1. VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China
  2. Vistagen Shares Fall Under $1 After Depression Drug Flunks Midstage Trial
  3. VistaGen Reports Top Line Results from NIMH's Exploratory Study of AV-101 Monotherapy for Treatment-Resistant Depression
  4. The VistaGen Therapeutics (NASDAQ:VTGN) Share Price Is Down 88% So Some Shareholders Are Rather Upset
  5. VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019
  6. Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder
  7. VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101
  8. VistaGen Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019
  9. VistaGen Therapeutics Receives Notice of Allowance for Additional U.S. Patent Regarding Methods of Production for AV-101
  10. VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019
  11. Four Tech Stocks Looking To Test February Highs
  12. VistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
  13. VistaGen Therapeutics Announces Proposed Public Offering of Common Stock
  14. VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia
  15. FDA Panel Nod for J&J's Esketamine Is Good News for Allergan, Vistagen
  16. VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
  17. The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering
  18. VistaGen Therapeutics Reports Fiscal 2019 Third Quarter Financial Results
  19. VistaGen Therapeutics to Present at the 21st Annual BIO CEO & Investor Conference on February 11, 2019
  20. AV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies